Go to The Journal of Clinical Investigation
Insight white on transparent.20160208
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising/recruitment
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All...
  • Videos
  • Collections
    • Recently published
    • Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

Insight white on transparent small

  • About
  • Editors
  • Consulting Editors
  • For authors
  • Transfers
  • Current issue
  • Past issues
  • By specialty
  • Contact
  • Recently published
  • Technical Advances
  • Clinical Medicine
  • Editorials
  • Top read articles
Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology
Stephanie R. Harrison, … , Michael F. McDermott, Sinisa Savic
Stephanie R. Harrison, … , Michael F. McDermott, Sinisa Savic
Published May 5, 2016
Citation Information: JCI Insight. 2016;1(6):e86336. https://doi.org/10.1172/jci.insight.86336.
View: Text | PDF
Categories: Clinical Medicine Immunology Inflammation

Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology

  • Text
  • PDF
Abstract

BACKGROUND. Some adult patients presenting with unexplained pyrexia, serositis, skin rashes, arthralgia, myalgia, and other symptoms commonly found in autoinflammatory disorders may not fit a specific diagnosis, either because their clinical phenotype is nondiagnostic or genetic tests are negative. We used the term undifferentiated systemic autoinflammatory disorder (uSAID) to describe such cases. Given that well-defined autoinflammatory diseases show responses to IL-1 blockade, we evaluated whether anakinra was useful for both diagnosing and treating uSAID patients.

METHODS. We performed a retrospective analysis of consecutive patients presenting with uSAID between 2012–2015 who were treated with the recombinant IL-1 receptor antagonist anakinra. uSAID was diagnosed after excluding malignancy, infection, and pathogenic mutations in known hereditary fever syndromes (HFS) genes and where clinical criteria for adult onset Still’s disease (AOSD) were not met.

RESULTS. A total of 11 patients presented with uSAID (5 males and 6 females), with a mean time to diagnosis of 3.5 years (1–8 years). Patients were unresponsive or only partially controlled on disease-modifying antirheumatic drug (DMARD)/steroid treatment. Anakinra controlled symptoms within 4–6 weeks of starting treatment in 9 of 11 cases. Two patients discontinued therapy — one due to incomplete response and another due to severe injection-site reactions.

CONCLUSION. This retrospective case series demonstrates that the spectrum of poorly defined autoinflammatory disorders that show responsiveness to anakinra is considerable. Anakinra seems a viable treatment option for these patients, who are unresponsive to standard steroid/DMARD treatments. Moreover, given the mechanisms of action, response to anakinra implicates underlying IL-1 dysregulation in the disease pathogenesis of responding uSAIDs patients.

Authors

Stephanie R. Harrison, Dennis McGonagle, Sharmin Nizam, Stephen Jarrett, Jeroen van der Hilst, Michael F. McDermott, Sinisa Savic

×

Figure 1

uSAID-01: serial CRP measurements.

Options: View larger image (or click on image) Download as PowerPoint
uSAID-01: serial CRP measurements.
This figure shows the serial CRP meas...
This figure shows the serial CRP measurements recorded for uSAID-01 from initial presentation to Dec. 2015. CRP, C-reactive protein; PMR, polymyalgia rheumatica; Pred, prednisolone; PUO, pyrexia of unknown origin; RA, rheumatoid arthritis; MTX, methotrexate.
Follow JCI Insight: Facebook logo white Twitter logo v2 Rss icon
Copyright © 2019 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts